<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="app1table4" position="float"><object-id pub-id-type="doi">10.7554/eLife.32638.041</object-id><label>Appendix 1&#8212;table 4.</label><caption><title>Estimated free [NAD<sup>+</sup>] and [NADPH]/[NADP<sup>+</sup>] of pharmacologically treated U2OS cells measured by flow cytometry.</title></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Free [NAD<sup>+</sup>] (&#181;M)</th><th colspan="2">Free [NADPH]/[NADP<sup>+</sup>] ratio</th></tr><tr><th>Compound</th><th>Cytosol</th><th>Mitochondria</th><th>Cytosol</th><th>Mitochondria</th></tr></thead><tbody><tr><td>Control</td><td>132 (&#177;&#160;29)</td><td>96 (&#177;&#160;20)</td><td>72 (&#177;&#160;8)</td><td>120 (&#177;&#160;14)</td></tr><tr><td>1 mM NA</td><td>162 (&#177;&#160;33)</td><td>n.d.</td><td>52 (&#177;&#160;6)</td><td>119 (&#177;&#160;14)<sup>&#8224;</sup></td></tr><tr><td>10 mM NAM</td><td>146 (&#177;&#160;30)</td><td>n.d.</td><td>87 (&#177;&#160;10)</td><td>n.d.</td></tr><tr><td>1 mM NMN</td><td>198 (&#177;&#160;41)</td><td>n.d.</td><td>59 (&#177;&#160;7)</td><td>114 (&#177;&#160;14)<sup>&#8224;</sup></td></tr><tr><td>10 mM NR</td><td>210 (&#177;&#160;43)</td><td>n.d.</td><td>60 (&#177;&#160;7)</td><td>120 (&#177;&#160;14)<sup>&#8224;</sup></td></tr><tr><td>100 nM FK866</td><td>42 (&#177;&#160;9)</td><td>34 (&#177;&#160;7)</td><td>88 (&#177;&#160;10)</td><td>116 (&#177;&#160;14)<sup>&#8224;</sup></td></tr><tr><td>1 mM 6-AN</td><td>n.d.</td><td>n.d.</td><td>35 (&#177;&#160;5)</td><td>n.d.</td></tr><tr><td>1 mM Metformin</td><td>168 (&#177;&#160;35)</td><td>80 (&#177;&#160;17)</td><td>49 (&#177;&#160;6)</td><td>90 (&#177;&#160;10)</td></tr><tr><td>1 mM Phenformin</td><td>213 (&#177;&#160;45)</td><td>72 (&#177;&#160;15)</td><td>45 (&#177;&#160;6)</td><td>54 (&#177;&#160;6)</td></tr><tr><td>10 &#181;M Rotenone</td><td>300 (&#177;&#160;64)</td><td>81 (&#177;&#160;17)</td><td>29 (&#177;&#160;4)</td><td>47 (&#177;&#160;6)</td></tr><tr><td>25 &#181;M Oligomycin A</td><td>101 (&#177;&#160;21)</td><td>24 (&#177;5)</td><td>121 (&#177;&#160;24)</td><td>open sensor*</td></tr></tbody></table><table-wrap-foot><fn><p>Values represent the mean estimated concentrations and ratios (&#177;&#160;SD) of three independent measurements performed in triplicate. The TMR/FRET ratios were converted into concentration using <xref ref-type="disp-formula" rid="equ7 equ8">Equations 7 and 8</xref>, where R<sub>max</sub> was determined in situ by incubating 10 min the cells with 2 mM sulfapyridine. R<sub>min</sub> was calculated from the in vitro maximum FRET ratio change &#916;R<sub>max</sub> (R<sub>min</sub>&#160;=&#160;R<sub>max</sub>/&#916;R<sub>max</sub>). c<sub>50</sub> and r<sub>50</sub> were determined from in vitro titrations at 25&#160;&#176;C. Control: untreated cells (full growth medium with 25 mM glucose), NA: nicotinic acid, Nam: nicotinamide, NMN: nicotinamide mononucleotide, NR: nicotinamide riboside, FK866: (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]&#8722;3-(pyridin-3-yl)acrylamide, 6-AN: 6-aminonicotinamide.</p><p>*The sensor reached full opening with this treatment [NADPH]/[NADP<sup>+</sup>]&#160;&#8805;&#160;300.</p></fn><fn><p>&#8224;The effect of the treatment is not statistically different compared to the control condition (p&#160;&#8805;&#160;0.05 using a two-tailed Student&#8217;s <italic>t</italic>-test). n.d., not determined.</p></fn></table-wrap-foot></table-wrap>